SCHEMBL980058

SCHEMBL980058

CCn1ncc(Cl)c(Cl)c1=O

nearest known ligand 0.60

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
HTT P42858 14/20 0.60
ALDH1A1 P00352 14/20 0.60
SMN1; SMN2 Q16637 6/20 0.60
KMT2A Q03164 5/20 0.60
GAA P10253 2/20 0.60
RAB9A P51151 13/20 0.58
NPSR1 Q6W5P4 12/20 0.58
MAPT P10636 10/20 0.58
NPC1 O15118 8/20 0.58
LMNA P02545 7/20 0.58
MITF O75030 6/20 0.58
RECQL P46063 1/20 0.58
POLB P06746 4/20 0.56
MEN1 O00255 4/20 0.56
PKM P14618 2/20 0.56
BLM P54132 1/20 0.56
GPR35 Q9HC97 1/20 0.56
CYP1A2 P05177 2/20 0.53
CYP2C19 P33261 2/20 0.53
CYP3A4 P08684 1/20 0.53

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL9234092 0.85 HTT (0.57) HTTALDH1A1SMN1; SMN2KMT2AGAA
SCHEMBL15674013 0.83 HTT (0.59) HTTALDH1A1SMN1; SMN2KMT2AGAA
SCHEMBL10572472 0.82 KMT2A (0.50) HTTALDH1A1SMN1; SMN2KMT2AGAA
SCHEMBL2361037 0.82 HTT (0.54) HTTALDH1A1SMN1; SMN2KMT2AGAA
SCHEMBL9828927 0.81 GAA (0.57) HTTALDH1A1SMN1; SMN2KMT2AGAA
SCHEMBL9726553 0.81 KMT2A (0.49) HTTALDH1A1SMN1; SMN2KMT2AGAA
SCHEMBL15674046 0.80 HTT (0.58) HTTALDH1A1SMN1; SMN2KMT2AGAA
SCHEMBL14574536 0.80 HTT (0.56) HTTALDH1A1SMN1; SMN2KMT2AGAA
SCHEMBL2319525 0.79 HTT (0.55) HTTALDH1A1SMN1; SMN2KMT2AGAA
SCHEMBL1372817 0.79 HTT (0.56) HTTALDH1A1SMN1; SMN2KMT2AGAA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-120081829-A Pyrimidinamine compound containing pyridazinone, and preparation method and application thereof 沈阳中化农药化工研发有限公司 2025-06-03 CN disclosed
US-20230391730-A1 INHIBITORS OF THE BROMODOMAIN PHD FINGER TRANSCRIPTION FACTOR (BPTF) AS ANTI-CANCER AGENTS REGENTS OF THE UNIVERSITY OF MINNESOTA 2023-12-07 US disclosed
WO-2022076735-A1 INHIBITORS OF THE BROMODOMAIN PHD FINGER TRANSCRIPTION FACTOR (BPTF) AS ANTI-CANCER AGENTS REGENTS OF THE UNIVERSITY OF MINNESOTA (US) 2022-04-14 WO disclosed
EP-2456765-B1 IMIDAZOLE DERIVATIVES AS MGLUR5 ANTAGONISTS HOFFMANN LA ROCHE (CH) 2013-05-01 EP disclosed
US-8334287-B2 Imidazoles HOFFMANN-LA ROCHE INC. (US) 2012-12-18 US disclosed
EP-2456765-A1 IMIDAZOLE DERIVATIVES AS MGLUR5 ANTAGONISTS F. Hoffmann-La Roche AG (CH) 2012-05-30 EP disclosed
WO-2011006910-A1 IMIDAZOLE DERIVATIVES AS MGLUR5 ANTAGONISTS F. HOFFMANN-LA ROCHE AG (CH) 2011-01-20 WO disclosed
US-20110015202-A1 IMIDAZOLES F. HOFFMANN-LA ROCHE AG (CH) 2011-01-20 US disclosed
US-5098900-A Reducing contractions in smooth muscles NISSAN CHEMICAL INDUSTRIES LTD. (JP) 1992-03-24 US disclosed
EP-0193853-B1 3(2H)PYRIDAZINONE, PROCESS FOR ITS PREPARATION AND ANTI-ALLERGIC AGENT CONTAINING IT NISSAN CHEMICAL INDUSTRIES LTD. (JP) 1990-09-12 EP disclosed
EP-0186817-B1 3(2H)PYRIDAZINONE, PROCESS FOR ITS PREPARATION AND ANTI-ALLERGIC AGENT CONTAINING IT NISSAN CHEMICAL INDUSTRIES LTD. (JP) 1989-08-02 EP disclosed
US-4783462-A 3(2H)pyridazinone, and anti-allergic agent containing it NISSAN CHEMICAL INDUSTRIES LTD. (JP) 1988-11-08 US disclosed
EP-0193853-A2 3(2H)pyridazinone, process for its preparation and anti-allergic agent containing it NISSAN CHEMICAL INDUSTRIES LTD. (JP) 1986-09-10 EP disclosed
EP-0186817-A1 3(2H)pyridazinone, process for its preparation and anti-allergic agent containing it NISSAN CHEMICAL INDUSTRIES LTD. (JP) 1986-07-09 EP disclosed
EP-0014562-B1 PYRIDAZINES FOR USE IN TREATING FUNGAL INFECTIONS, PHARMACEUTICAL COMPOSITIONS CONTAINING THEM, AND PROCESSES FOR THEIR PREPARATION Pfizer Limited (GB) 1983-10-05 EP disclosed
EP-0014562-A1 Pyridazines for use in treating fungal infections, pharmaceutical compositions containing them, and processes for their preparation Pfizer Limited (GB) 1980-08-20 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110015202-A1 IMIDAZOLES GRM5, GRM1, GRIK5 HTT 1711/4885ALDH1A1 1642/4885SMN1; SMN2 2414/4885
US-20230391730-A1 INHIBITORS OF THE BROMODOMAIN PHD FINGER TRANSCRIPTION FACTOR (BPTF) AS ANTI-CANCER AGENTS BPTF, BRPF3, PHF6 HTT 1313/4885ALDH1A1 2997/4885SMN1; SMN2 4839/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.